IOVA — Iovance Biotherapeutics Share News
0.000.00%
Last trade - 00:00- $6.67bn
- $6.37bn
- $263.50m
US RESEARCH ROUNDUP-BlackRock, Evercore, Goldman Sachs
Brief: Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., As Chief Medical Officer
Iovance hits two-year high after raising annual revenue forecast
U.S. RESEARCH ROUNDUP- Berkshire Hathaway, Exxon Mobil, Honeywell Technologies
Replimune slides as FDA approval label tempers enthusiasm
US FDA approves Replimune's skin cancer drug after prior rejections (updated)
US FDA approves Replimune's skin cancer drug
U.S. STOCKS ON THE MOVE-Braveheart Bio, Paysign, Hertz Global
Iovance shares soar after Q2 revenue beat
U.S. STOCKS ON THE MOVE-Ralph Lauren, Sempra, Parker-Hannifin, Lincoln International
Iovance Biotherapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
U.S. STOCKS ON THE MOVE- MACOM Technology , Becton Dickinson, Centrus Energy
Iovance gains after Q2 revenue beat
Iovance Q2 net loss narrows
Brief: Iovance Biotherapeutics Q2 Revenue USD 99.313 Million
Brief: Iovance Biotherapeutics Inc Files For Mixed Shelf
Brief: Iovance's Amtagvi Granted Approval For Treatment Of Advanced Melanoma In Australia
Brief: Iovance Biotherapeutics Announces Clearance Of Investigational New Drug (Ind) Application For Il-12 Tethered Til Therapy IOV-5001
U.S. STOCKS ON THE MOVE-Krispy Kreme, Tesla, Axon Enterprise